Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00427544 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety, Tolerability, and PK of PRA-027 Administered to Women of Nonchildbearing Potential
A Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00427544 is a Phase 1 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer.
The verdict
NCT00427544, a Phase 1 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
The primary purpose of this study is to asess the safety and tolerability of ascending single oral doses of PRA-027 in healthy women of nonchildbearing potential. The secondary purpose is to provide the initial pharmacokinetic (PK) and pharmacodynamic (PD) profile of PRA-027 in healthy women of nonchildbearing potential, and to evaluate the effect of a high-fat meal on the PK and PD of PRA-027 administered to healthy women of nonchildbearing potential.
Interventions
- DRUG PRA-027
Trial Details
| Field | Value |
|---|---|
| Start Date | 2007-02 |
| Est. Completion | 2007-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00427544
The ClinicalTrials.gov registry entry for NCT00427544 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PRA-027 is the first listed.
NCT00427544 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00427544 about?
NCT00427544 is a clinical study titled "Study of the Safety, Tolerability, and PK of PRA-027 Administered to Women of Nonchildbearing Potential". The primary purpose of this study is to asess the safety and tolerability of ascending single oral doses of PRA-027 in healthy women of nonchildbearing potential. The secondary purpose is to provide the initial pharmacokinetic (PK) and pharmacodynamic (PD) profile of PRA-027 in healthy women of nonc...
What is the current status of trial NCT00427544?
This trial is currently completed. It is a Phase 1 study. The study started on 2007-02. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00427544?
The interventions under investigation include: PRA-027 (DRUG).
Who is sponsoring clinical trial NCT00427544?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.